98%
921
2 minutes
20
Drug-drug interactions (DDIs) pose a significant and intricate challenge in clinical pharmacotherapy, especially among older adults who often have chronic conditions that necessitate multiple medications. These interactions can undermine the effectiveness of treatments or lead to adverse drug reactions (ADRs), which in turn can increase illness rates and strain healthcare resources. Traditional methods for detecting DDIs, such as clinical trials and spontaneous reporting systems, tend to be retrospective and frequently fall short in identifying rare, population-specific, or complex DDIs. However, recent advancements in artificial intelligence (AI), systems pharmacology, and real-world data analytics have paved the way for more proactive and integrated strategies for predicting DDIs. Innovative techniques like graph neural networks (GNNs), natural language processing, and knowledge graph modeling are being increasingly utilized in clinical decision support systems (CDSS) to improve the detection, interpretation, and prevention of DDIs across various patient demographics. This review aims to provide a thorough overview of the latest trends and future directions in DDIs research, structured around five main areas: (1) epidemiological trends and high-risk drug combinations, (2) mechanistic classification of DDIs, (3) methodologies for detection and prediction, particularly those driven by AI, (4) considerations for vulnerable populations, and (5) regulatory frameworks and pathways for innovation. Special emphasis is placed on the role of pharmacogenomic insights and real-world evidence in developing personalized strategies for assessing DDIs risks. By connecting fundamental pharmacological principles with advanced computational technologies, this review seeks to guide clinicians, researchers, and regulatory bodies. The integration of AI, multi-omics data, and digital health systems has the potential to significantly enhance the safety, accuracy, and scalability of DDIs management in contemporary healthcare.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12380558 | PMC |
http://dx.doi.org/10.3389/fphar.2025.1618701 | DOI Listing |
Front Biosci (Landmark Ed)
August 2025
Animal Genetics, University of Tuebingen, 72076 Tuebingen, Germany.
Background: Membrane transport proteins are critical determinants of systemic and intracellular drug levels, thereby contributing substantially to drug response and/or adverse drug reactions. Therefore, the U.S.
View Article and Find Full Text PDFPharmacotherapy
September 2025
Department of Biomedical Informatics, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear.
View Article and Find Full Text PDFJ Infect Public Health
September 2025
AP-HP, Hospital Bichat - Claude-Bernard, Infectious and Tropical Diseases Department, IAME UMR 1137 INSERM, Université Paris Cité, France; IMEA, Hospital Bichat-Claude Bernard, Paris, France.
Background: Polymedication and comorbidities are frequent in aging people with HIV (PWH) and often associated with elevated incidences of adverse events (AEs) and drug-drug interactions (DDIs). The objective of this study was to evaluate the efficacy, safety and practicality of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), an antiretroviral (ARV) therapy with limited DDIs, in an elderly virologically-controlled PWH population.
Materials And Methods: This study was prospective, multicentric, single-arm conducted in HIV-1 controlled PWH aged over 65 years who switched from a ritonavir- or cobicistat-boosted containing regimen to B/F/TAF.
Infect Drug Resist
August 2025
Department of Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China.
Purpose: To determine the real-world patterns and extent of potential drug-drug interactions (DDIs) related to nirmatrelvir/ritonavir (NMVr) in China.
Patients And Methods: Data on NMVr-treated patients from over 160 hospitals across 9 Chinese cities from January 2022 to December 2023 were extracted from the Hospital Prescription Analysis (HPA) database, which was established in Beijing in 1997 to promote rational medication use in China. Grade C, D and X DDIs from the Lexicomp database were defined as clinically significant and analyzed in this study.
J Chem Inf Model
September 2025
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, China.
Drug-drug interactions (DDIs) present a significant challenge in clinical practice, as they may lead to adverse reactions, diminished therapeutic efficacy, and serious risks to patient safety. However, most existing methods depend on single-view representations of drug molecules or substructures, which limits their capacity to capture the diverse and complex nature of drug properties. To overcome this limitation, we propose MGRL-DDI, a multiview graph representation learning framework that comprehensively models drug structures from three complementary perspectives: Three-dimensional (3D) molecular graphs, motif graphs, and molecular graphs.
View Article and Find Full Text PDF